Answer
Rukobia (fostemsavir tromethamine) is not recommended for HIV-1 Group M subtype CRF01_AE infection because available data indicate naturally occurring resistance to temsavir, with considerably reduced antiviral activity against this subtype.
Sources for this answer
- Rukobia 600 mg prolonged-release tabletsViiV Healthcare UK Ltd · emc · SmPC §4.4 Special warnings and precautions for use · Version 6Document updated
Sources checked